Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

2.200 +0.050 (+2.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,257,101
Open 2.150
Bid (Size) 2.180 (8)
Ask (Size) 2.200 (32)
Prev. Close 2.150
Today's Range 2.125 - 2.230
52wk Range 1.760 - 18.04
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks With Key Catalysts Coming in December
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. 
Via InvestorPlace

Performance

YTD
-85.10%
-85.10%
1 Month
-6.38%
-6.38%
3 Month
-70.94%
-70.94%
6 Month
-78.45%
-78.45%
1 Year
-87.03%
-87.03%

More News

Read More
What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Via Benzinga
DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Earnings Outlook For Arcutis Biotherapeutics
Via Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In November
Via Benzinga
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
MSP Recovery And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For November 3, 2023
Via Benzinga
Arcutis to Report Third Quarter 2023 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Nasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Arcutis Announces Pricing of $100 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
Via Benzinga
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.